IPCI.H — Intellipharmaceutics International Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -285.07% | ||
Financial Summary
| Year End 30th Nov | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.71 | 3.48 | 1.4 | n/a | 0.07 | n/a | n/a | -58.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract (GIT), diabetes and pain. Its product portfolio includes Oxycodone Hydrochloride ER, Regabatin, Dexmethylphenidate ER, Metformin ER, Venlafaxine ER, Pantoprazole ER, Quetiapine ER, Lamotrigine ER, Levetiracetam ER, Desvenlafaxine ER, Ranolazine ER, and Carvedilol ER. Its product portfolio includes both new products and controlled-release generic products. It also provides analytical services.
Directors
- Isa Odidi CHM
- Amina Odidi PRE
- Patrick Yat VPR
- Norman Betts IND (67)
- Shawn Graham IND
- Kenneth Keirstead IND
- Bahadur Madhani IND
- Last Annual
- November 30th, 2022
- Last Interim
- August 31st, 2023
- Incorporated
- October 22nd, 2009
- Public Since
- July 22nd, 1999
- No. of Employees
- 33
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 33,092,665
- Address
- 30 Worcester Rd, ETOBICOKE, M9W 5X2
- Web
- https://www.intellipharmaceutics.com
- Phone
- +1 4167983001
- Auditors
- MNP LLP
Upcoming Events for IPCI.H
Q2 2024 Intellipharmaceutics International Inc Earnings Release
Intellipharmaceutics International Inc Annual Shareholders Meeting
Q3 2024 Intellipharmaceutics International Inc Earnings Release
Similar to IPCI.H
Eve & Co
TSX Venture Exchange
Indiva
TSX Venture Exchange
Khiron Life Sciences
TSX Venture Exchange
Lumiera Health
TSX Venture Exchange
Radient Technologies
TSX Venture Exchange
FAQ
What is the Intellipharmaceutics International share price?
As of Today at 21:22 UTC, shares in Intellipharmaceutics International are trading at . This share price information is delayed by 15 minutes.
How has the Intellipharmaceutics International share price performed this year?
Shares in Intellipharmaceutics International last closed at and the price had moved by +6.67% over the past 365 days. In terms of relative price strength the Intellipharmaceutics International share price has underperformed the Toronto Stock Exchange 300 Composite Index by -3.91% over the past year.
What are the analyst and broker recommendations for Intellipharmaceutics International?
There is no consensus recommendation for this security.
What is the Intellipharmaceutics International dividend yield?
Intellipharmaceutics International does not currently pay a dividend.
Does Intellipharmaceutics International pay a dividend?
Intellipharmaceutics International does not currently pay a dividend.
When does Intellipharmaceutics International next pay dividends?
Intellipharmaceutics International does not currently pay a dividend.
How do I buy Intellipharmaceutics International shares?
To buy shares in Intellipharmaceutics International you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Intellipharmaceutics International?
As of the previous close price of , shares in Intellipharmaceutics International had a market capitalisation of .
Where are Intellipharmaceutics International shares listed?
Here are the trading details for Intellipharmaceutics International:
- Country of listing: Canada
- Exchange: NEX
- Ticker Symbol: IPCI.H
What kind of share is Intellipharmaceutics International?
Based on an overall assessment of its quality, value and momentum Intellipharmaceutics International is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Intellipharmaceutics International share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Intellipharmaceutics International share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Intellipharmaceutics International. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -17.9%.
As of the last closing price of , shares in Intellipharmaceutics International were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Intellipharmaceutics International PE Ratio?
The Intellipharmaceutics International PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at .
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Intellipharmaceutics International?
Intellipharmaceutics International's management team is headed by:
- Isa Odidi - CHM
- Amina Odidi - PRE
- Patrick Yat - VPR
- Norman Betts - IND
- Shawn Graham - IND
- Kenneth Keirstead - IND
- Bahadur Madhani - IND